← Back to front page
Oceania · General news · The Mercury

The quiet catalyst: Why open-label extension trials matter for ASX biotechs

Published by The Mercury · Australia 11 h ago

While main trial results tend to attract the big headlines for biotech companies, lower-profile open-label extension (OLE) trials can tell an equally important story.

Read the full article on The Mercury Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.themercury.com.au)

Also worth reading

ABC News Australia

AFL sets date and time of AFL Origin between WA and SA

 WAtoday

Bavuma turns Test match as Australia cornered

 The Age

Starc says no tantrums from Lyon after ‘dodgy prawn’ fells Hazlewood

 Brisbane Times

Starc says no tantrums from Lyon after ‘dodgy prawn’ fells Hazlewood

 iTnews

Optus chasing "near real-time" data as regulatory pressure looms

 The Conversation AU

One in six older people experience abuse in NZ, with psychological harm most common